K. Kotrych, T. Sulikowski, L. Domański, M. Białecka, M. Droździk
{"title":"Polymorphism in the P-glycoprotein drug transporter MDR1 gene in renal transplant patients treated with cyclosporin A in a Polish population.","authors":"K. Kotrych, T. Sulikowski, L. Domański, M. Białecka, M. Droździk","doi":"10.1097/00008571-200305000-00004","DOIUrl":null,"url":null,"abstract":"P-glycoprotein (P-gp), the product of MDR1 gene, is a protein which mediates transmembrane transport of a great number of xenobiotics including cyclosporin A used as an immunosuppressive drug in patients with allogenic kidney grafts. The P-gp activity and expression is dependent on the MDR1 gene polymorphism in position C3435T of exon 26. In this study, C3435T polymorphism was analyzed in 116 patients with allogenic kidney graft treated with cyclosporin Aand 144 randomly selected healthy individuals. The prevalence of MDR1 gene genotypes 3435CC, 3435CT, 3435TT were also compared in patients after allogenic kidney graft with both acute and chronic graft rejection (48 patients with acute and 76 with chronic graft rejection) and control groups (respectively 139 and 112). The results of the study demonstrated that the allelic frequency and MDR1 genotype distribution were similar in all evaluated groups. It was revealed that MDR1 gene polymorphism was not a predisposing factor for terminal kidney failure leading to renal transplantation. Moreover, evaluation of C3435T polymorphism of MDR1 gene will probably not be useful for characterization of groups of patients at increased risk of acute and chronic kidney graft rejection.","PeriodicalId":166986,"journal":{"name":"Pharmacological reports : PR","volume":"1 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2007-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"21","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacological reports : PR","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/00008571-200305000-00004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 21
Abstract
P-glycoprotein (P-gp), the product of MDR1 gene, is a protein which mediates transmembrane transport of a great number of xenobiotics including cyclosporin A used as an immunosuppressive drug in patients with allogenic kidney grafts. The P-gp activity and expression is dependent on the MDR1 gene polymorphism in position C3435T of exon 26. In this study, C3435T polymorphism was analyzed in 116 patients with allogenic kidney graft treated with cyclosporin Aand 144 randomly selected healthy individuals. The prevalence of MDR1 gene genotypes 3435CC, 3435CT, 3435TT were also compared in patients after allogenic kidney graft with both acute and chronic graft rejection (48 patients with acute and 76 with chronic graft rejection) and control groups (respectively 139 and 112). The results of the study demonstrated that the allelic frequency and MDR1 genotype distribution were similar in all evaluated groups. It was revealed that MDR1 gene polymorphism was not a predisposing factor for terminal kidney failure leading to renal transplantation. Moreover, evaluation of C3435T polymorphism of MDR1 gene will probably not be useful for characterization of groups of patients at increased risk of acute and chronic kidney graft rejection.
p -糖蛋白(P-gp)是MDR1基因的产物,是一种介导包括环孢素a在内的大量异种生物的跨膜转运的蛋白质,用于异体肾移植患者的免疫抑制药物。P-gp的活性和表达依赖于26外显子C3435T位置的MDR1基因多态性。本研究分析了116例接受环孢素a治疗的同种异体肾移植患者和144例随机选择的健康个体的C3435T多态性。同时比较了MDR1基因型3435CC、3435CT、3435TT在同种异体肾移植术后急性和慢性排斥反应患者(48例急性排斥反应患者和76例慢性排斥反应患者)和对照组(分别为139例和112例)中的患病率。研究结果表明,所有评估组的等位基因频率和MDR1基因型分布相似。结果表明,MDR1基因多态性不是导致肾移植的终末期肾衰竭的易感因素。此外,MDR1基因C3435T多态性的评估可能对急性和慢性肾移植排斥风险增加的患者群体的特征没有帮助。